We randomly assigned 231 adults with well-controlled human immunodeficiency virus infection at a ratio of 2:2:2:1 to receive 40 % of the standard dose of IPV intradermally , 20 % of the standard dose intradermally , the full standard dose intramuscularly , or 40 % of the standard dose intramuscularly .